IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Barnes Pettey Financial Advisors LLC

Barnes Pettey Financial Advisors LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 966 shares of the medical research company’s stock after selling 82 shares during the quarter. Barnes Pettey Financial Advisors LLC’s holdings in IQVIA were worth $229,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. 1832 Asset Management L.P. lifted its stake in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after acquiring an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter valued at $70,610,000. Impax Asset Management Group plc boosted its holdings in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after purchasing an additional 264,555 shares during the last quarter. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of IQVIA by 285.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock valued at $56,783,000 after buying an additional 198,808 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Up 1.4 %

NYSE IQV opened at $214.63 on Friday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market capitalization of $39.11 billion, a P/E ratio of 29.32, a PEG ratio of 2.22 and a beta of 1.49. The firm’s 50-day moving average is $237.63 and its two-hundred day moving average is $230.49. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Truist Financial dropped their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a research report on Wednesday. Royal Bank of Canada started coverage on IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price on the stock. Finally, Robert W. Baird increased their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $267.27.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.